OncoMatch/Clinical Trials/NCT07737171
Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions
Official title: Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions: A Pancardinal-4 Prospective Registry
Is NCT07737171 recruiting? Yes, currently enrolling (Oct 2026). Studying Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) for pancreatic cancer.
Treatment: Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) — This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Prior therapy
Must have received: endoscopic ultrasound-guided radiofrequency ablation — treatment of pancreatic lesions
Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas Health Science Center at Houston · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07737171 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received endoscopic ultrasound-guided radiofrequency ablation.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages